Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea : Episode 1

Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera

May 1, 2024

Opinion

Video

Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, introduce themselves and provide insights on the prevalence of hydroxyurea resistance or intolerance in patients with polycythemia vera (PV) and how it impacts treatment decisions and costs.

Now Viewing

EP: 1.Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera

EP: 2.The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance

EP: 3.Objectives and Study Design of MAJIC-PV

EP: 4.Inside MAJIC-PV: A Closer Look at the Patient Population

EP: 5.Key Findings from MAJIC-PV

EP: 6.Safety Analysis and Interpreting Results from MAJIC-PV

EP: 7.Key Takeaways Following MAJIC-PV

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!